IRIS
FRANCINI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.893
EU - Europa 8.231
AS - Asia 1.414
SA - Sud America 21
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 7
Totale 20.601
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.855
GB - Regno Unito 2.470
IE - Irlanda 1.626
CN - Cina 1.232
UA - Ucraina 1.211
SE - Svezia 902
FR - Francia 596
DE - Germania 586
IT - Italia 408
FI - Finlandia 274
VN - Vietnam 63
ES - Italia 37
IN - India 35
CA - Canada 34
NL - Olanda 25
BE - Belgio 21
TR - Turchia 21
AU - Australia 17
EU - Europa 15
RU - Federazione Russa 15
CL - Cile 12
HK - Hong Kong 12
DK - Danimarca 10
IR - Iran 10
JP - Giappone 8
RO - Romania 8
PL - Polonia 7
BG - Bulgaria 5
BR - Brasile 5
BD - Bangladesh 4
HU - Ungheria 4
SG - Singapore 4
AR - Argentina 3
IL - Israele 3
IM - Isola di Man 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
SA - Arabia Saudita 3
TH - Thailandia 3
AM - Armenia 2
AT - Austria 2
AZ - Azerbaigian 2
BZ - Belize 2
CH - Svizzera 2
CY - Cipro 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
MA - Marocco 2
MC - Monaco 2
MW - Malawi 2
RS - Serbia 2
TW - Taiwan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MX - Messico 1
NG - Nigeria 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 20.601
Salva come PNG Salva come JPEG
Città #
Southend 2.226
Fairfield 1.656
Dublin 1.610
Chandler 1.011
Jacksonville 993
Ashburn 888
Woodbridge 846
Wilmington 687
Seattle 655
Houston 613
Cambridge 520
Nanjing 365
Ann Arbor 358
Princeton 333
Beijing 259
New York 229
San Mateo 155
Siena 154
Boardman 136
Nanchang 122
San Diego 97
Helsinki 72
Dong Ket 61
Hebei 53
Shenyang 53
Kunming 46
Norwalk 45
Shanghai 43
Tianjin 43
Changsha 41
Jiaxing 35
Málaga 32
Lancaster 29
Toronto 28
Ningbo 25
Hangzhou 24
Brussels 21
Düsseldorf 21
Fremont 21
San Francisco 21
London 20
Menlo Park 20
Zhengzhou 19
Jinan 17
Amsterdam 16
Auburn Hills 16
Los Angeles 16
Washington 16
Milan 14
Philadelphia 14
Redwood City 14
Frankfurt am Main 12
Kansas City 12
Hounslow 11
Izmir 11
Changchun 10
Dearborn 10
Lanzhou 10
Renton 10
Tappahannock 9
Edinburgh 8
Falls Church 8
Kilburn 8
Santiago 8
Delhi 7
Hong Kong 7
Melbourne 7
Paris 7
Taizhou 7
Venezia 7
Fuzhou 6
Guangzhou 6
Rome 6
San Jose 6
Sydney 6
Taastrup 6
Tokyo 6
Warsaw 6
Chicago 5
Mestre 5
Prescot 5
Sofia 5
Vijayawada 5
Catania 4
Haikou 4
Hyderabad 4
Kocaeli 4
Madrid 4
Reggio Calabria 4
Saint Petersburg 4
Udine 4
Winnipeg 4
Zanjan 4
Acton 3
Annoire 3
Bangkok 3
Florence 3
Greifswald 3
Groningen 3
Indiana 3
Totale 15.112
Salva come PNG Salva come JPEG
Nome #
Survival following early-stage colon cancer: An ACCENT-based comparison of patients versus a matched international general population 272
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. 214
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 186
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey 183
Peptidi epitopici immunogenici del CEA da utilizzare nella chemio-immunoterapia del carcinoma del colon-retto e della mammella. 175
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 173
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 161
A62Effectiveness and resulting surgical behavior after neoadjuvant chemotherapy in locally advanced breast cancer: our experience 159
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. 149
Folinic Acid and 5-Fluorouracil as adjuvant chemotherapy in colon cancer 143
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma 143
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 143
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation 141
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer 138
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia 138
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience 138
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. 135
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. 135
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. 134
Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy 133
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. 133
Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. 132
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens 132
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 132
Quality of life in advanced colorectal cancer 132
Virosoma dell'influenza immunoricostituito (IRIV) contenente il gene per CD40L come immunoprotettore tumorale CEA-specifico e usi immunogenici di esso. 132
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 131
70 Tumor associated hypercalcemia 131
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer 130
Bioactivity of GM-CSF and IL-2 in cancer patients 130
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 129
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study 129
Tumour associated antigen (TAA) specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes 128
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate 128
Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases 128
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid 128
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. 128
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 127
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane 125
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 125
Is endocrine hyperactivity a favourable prognostic factor in the chemotherapic treatment of bronchogenic carcinoma? 125
Palliative chemotherapy for relief of subocclusive symptoms 124
Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases 124
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 124
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies 123
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 123
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine 122
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 121
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. 121
A five-day treatment of tumor-induced hypercalcemia by intravenous amino-hexane (AHBP) or aminobutane (ABBP) bisphosphonate 121
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? 120
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. 120
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel 119
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity 119
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). 118
Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 118
Weekly chemotherapy in advanced prostatic cancer 117
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer 117
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma 117
Hepatoid gastric carcinoma. A case report 116
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia. 115
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 115
Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation 114
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials 114
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. 114
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen 113
Squamocellular gallbladder carcinoma associated with multiple small pigment stones long term after total gastrectomy 113
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients 113
Weekly chemotherapy in advanced prostatic cancer 113
Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer 113
Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy 113
Seasonal variation in urinary excretion of cyclic AMP in healthy people 112
Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine 112
Weekly epirubicin in patients with hormone-resistant prostate cancer 111
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma 108
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 108
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients 107
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials 107
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy 106
In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse 106
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 106
Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. 106
Serum osteocalcin concentration in patients with prostatic cancer 105
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase 105
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer 105
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. 105
Hypercalcemia and urinary excretion of cyclic AMP in bronchogenic carcinoma 103
Models of active specific immuno-therapy of human malignancy bone metastases. 103
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. 102
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study 102
A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate camcer metastates, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2 102
Osteoblastic metastases: Metabolic and morphologic aspects 102
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study 102
PTH-rP related peptide cancer therapeutics 101
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. 101
PTH-RP related peptide cancer therapeutics. 100
Production of parathyroid hormone and parathyroid-hormone-related protein by breast cancer cells in culture 100
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens 100
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 100
CEA RELATED PEPTIDE CANCER THERAPEUTICS 99
Totale 12.468
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.025
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.025
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.297 0 0 0 0 0 0 0 0 0 243 560 494
2019/20204.613 574 142 338 764 252 274 330 697 374 432 109 327
2020/20214.016 196 408 98 349 306 588 155 600 482 238 329 267
2021/20222.434 180 310 201 195 103 62 102 97 133 264 243 544
2022/20233.640 240 211 455 543 360 805 62 327 396 59 121 61
2023/20242.121 116 60 171 73 63 771 781 39 3 44 0 0
Totale 20.748